Carmin Appolon
Emergency Medicine · Brooklyn, NYNPI 1124052394
Payments from drug & device makers
Across 271 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$807
- Lundbeck LLC$617
- Teva Pharmaceuticals USA, Inc.$512
- plus $805 from 8 others
What the payments were for
- Food & beverage$6,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 54 | $1,299 |
| Johnson & Johnson | 54 | $1,283 |
| Alkermes, Inc. | 47 | $1,017 |
| Otsuka America Pharmaceutical, Inc. | 37 | $807 |
| Lundbeck LLC | 26 | $617 |
| Teva Pharmaceuticals USA, Inc. | 20 | $512 |
| Sunovion Pharmaceuticals Inc. | 12 | $272 |
| AbbVie(2 entities) | 6 | $165 |
| Bioxcel Therapeutics, Inc. | 5 | $119 |
| Brainsway USA Inc | 2 | $73 |
| Indivior Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $55 |
| Janssen Scientific Affairs, LLC | 1 | $28 |
| Corium, LLC | 1 | $28 |
How this compares
$6,340 in reported general payments places this provider in the 95th percentile of 4,167 emergency medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $220,039 |
| Abilify MaintenaAripiprazole | 26 | $67,784 |
| Invega SustennaPaliperidone Palmitate | 20 | $43,385 |
| VraylarCariprazine Hcl | 11 | $16,000 |
| Aripiprazole | 130 | $3,257 |
| Fluphenazine Hcl | 11 | $1,309 |
| Quetiapine Fumarate | 76 | $1,150 |
| Divalproex Sodium | 74 | $880 |
| Zolpidem Tartrate | 106 | $711 |
| Buspirone Hcl | 84 | $646 |
| Mirtazapine | 61 | $635 |
| Bupropion XlBupropion Hcl | 58 | $564 |
| Sertraline Hcl | 154 | $516 |
| Paroxetine Hcl | 67 | $478 |
| Haloperidol | 30 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,299 | $220,03923 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $807 | $67,78426 claims |
| Johnson & JohnsonInvega Sustenna | $1,283 | $43,38520 claims |
| AbbVieVraylar | $165 | $16,00011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,167 emergency medicine providers in New York.
Other emergency medicine in Brooklyn
- Robert BirkhahnBrooklyn$475K
- Sergey MotovBrooklyn$233K
- Matthew KesselBrooklyn$139K
- Richard SinertBrooklyn$94K
- Uche BlackstockBrooklyn$79K
- Lorenzo PaladinoBrooklyn$32K
- Jennifer BallingerBrooklyn$20K
- Teresa SmithBrooklyn$19K
- Rondalph TaylorBrooklyn$15K
- Andrew SweenyBrooklyn$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.